← boardnext 2027-06next 2028-02
LBRX
LB Pharmaceuticals Inc.distress 2/10 · well-funded / low risk$35.33-1%today-1% from 52w high
Lead: major depressive disorder (MDD) · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$366M
Runway
6.6 yrs
Shares 1y
+13%
Price & events
+49.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+15.5%
1W
+15.4%
1M
+14.8%
3M
+47.7%
6M
—
1Y
—
2Y
—
5Y
+104.2%
All
Overview
- Market Cap
- $1.01B
- Volume
- 67.78K
- 52 Week Range
- $14.61 – $35.84
- Total Shares
- 28.68M
- Float Shares
- 18.10M
- Short %
- 19.09%
- % Held by Insiders
- 0.27%
- % Held by Institutions
- 107.15%
- RVOL
- 0.21x
Pipeline stages · 2 programs
LB-102 (50 mg tablet), LB-102 (100 mg tablet)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LB-102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | LB-102 (50 mg tablet), LB-102 (100 mg tablet) | Schizophrenia | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 2 | LB-102 | Bipolar I Disorder | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | LB-102 | Schizophrenia | — | not yet recruiting |
Catalyst news & presentations · 5
- first half of 2029Guided 55%readoutPhase 2LB-102 · Topline results for Phase 2 trial; primary endpoint MADRS-10 at week six.SEC 8-K
- first quarter of 2028readoutPhase 2LB-102 · Topline data from Phase 2 ILLUMINATE-1 trialSEC 8-K
- early 2027Guided 55%trial initiationsecondaryPhase 2LB-102 · Multi-center, randomized, double-blind, placebo-controlled trial evaluating two doses (15 mg and 25 mg) as adjunctive treatment, enrolling ~380 patients.SEC 8-K
- first half of 2027readoutPhase 3LB-102 · Topline results from pivotal Phase 3 NOVA-2 trialSEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $45 (+27% upside) · 7 analysts
- 2026-07-21BMO CapitalOutperform
- 2026-07-07Wolfe ResearchOutperform
- 2026-04-27HC Wainwright & Co.Buy
- 2026-04-10Craig-HallumBuy
- 2026-03-27StifelBuy
- 2025-12-11StifelBuy
Competitors — major depressive disorder (MDD)
- none identified
Recent news
- 2026-07-22LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year High - Time to Buy? - MarketBeat
- 2026-07-22Jennison Associates LLC Sells 283,636 Shares of LB Pharmaceuticals Inc $LBRX - MarketBeat
- 2026-07-21LBRX Initiated Coverage by BMO Capital -- Rated Outperform at $4 - GuruFocus
- 2026-07-21Price to book forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
- 2026-07-19LB Pharmaceuticals Inc (LBRX) Gains 2.68% as Shares Approach Key Resistance at $32.98 - Volatility Smile - dars.gov.et
- 2026-07-12LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
- 2026-07-10LB Pharmaceuticals Inc (LBRX) Slides 2.34% as Technical Support Levels Come into Focus - Stock Buy Zone - dars.gov.et
- 2026-07-07LB Pharmaceuticals Inc (LBRX) Gains 2.63% on Above-Average Volume, Tests Key Resistance at $36 - Call Wall - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.